Promising combo tackles Hard-to-Treat leukemia

This study tests a combination of low-intensity chemotherapy, a targeted drug called ponatinib, and an immunotherapy called blinatumomab in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL), a fast-growing blood cancer. The goal is to see if this approach can achieve deep remission in patients whose cancer is newly diagnosed or has returned or not responded to prior treatment. About 22 participants will receive the treatment in two phases, with researchers tracking how well the cancer responds and how long the effects last.